MIRA INFORM REPORT

 

 

Report Date :

11.12.2012

 

IDENTIFICATION DETAILS

 

Name :

MARPEL PHARMA S.A

 

 

Registered Office :

3 Calle A 4-24 Zona 10 Interior

 

 

Country :

Guatemala

 

 

Date of Incorporation :

13.10.2009

 

 

Legal Form :

Sociedad Anonima

 

 

Line of Business :

Distribution of Pharmaceutical Products

 

 

No. of Employees :

16

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2011)

Current Rating

(30.06.2012)

Guatemala

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

GUATEMALA - ECONOMIC OVERVIEW

 

Guatemala is the most populous country in Central America with a GDP per capita roughly one-half that of the average for Latin America and the Caribbean. The agricultural sector accounts for 13% of GDP and 38% of the labor force; key agricultural exports include coffee, sugar, bananas, and vegetables. The 1996 peace accords, which ended 36 years of civil war, removed a major obstacle to foreign investment, and since then Guatemala has pursued important reforms and macroeconomic stabilization. The Dominican Republic-Central American Free Trade Agreement (CAFTA-DR) entered into force in July 2006 spurring increased investment and diversification of exports, with the largest increases in ethanol and non-traditional agricultural exports. While CAFTA-DR has helped improve the investment climate, concerns over security, the lack of skilled workers and poor infrastructure continue to hamper foreign direct investment. The distribution of income remains highly unequal with the richest 20% of the population accountingfor more than 51% of Guatemala's overall consumption. More than half of the population is below the national poverty line and 13% of the population lives in extreme poverty. Poverty among indigenous groups, which make up 38% of the population, averages 73% and extreme poverty rises to 28%. Nearly one-half of Guatemala's children under age five are chronically malnourished, one of the highest malnutrition rates in the world. Given Guatemala's large expatriate community in the United States, it is the top remittance recipient in Central America, with inflows serving as a primary source of foreign income equivalent to nearly two-fifths of exports or one-tenth of GDP. Economic growth fell in 2009 as export demand from US and other Central American markets dropped and foreign investment slowed amid the global recession, but the economy recovered gradually in 2010-11 and will likely return to more normal growth rates in 2012.

 

Source : CIA

 

 

GEOPOLITICS - GUATEMALA

POLITICAL DATA

ECONOMIC DATA

Form of Government: Republic


Economic Risk: Low

Currency: 100.00 GTQ = 12.73USD

Branch Situation:Stable

 

 

IDENTIFICATION

Ordered as:

Marpel Pharma

Address in the order:

De Tips (Sabana) Sur 100 Oeste San

Comments on data supplied:

Dear Client:

 

The correct address is add below.

Legal Name:

MARPEL PHARMA S.A

Legal Address

3 Calle A 4-24 Zona 10 Interior Guatemala.

Telephone:

(502) 23608468 - 23608484, 23608452

NIT :

67680895

Fax:

(502) 23608466

Legal Form:

Sociedad Anonima

Email:

m.ramazzini@marpelpharma.com, m.ramirez@marpelpharma.com, s.sosa@marpelpharma.com

Registered in:

Guatemala

Website:

www.marpelpharma.com (In construction)

Date Created:

Octuber 13, 2009

Manager:

Mateo Estuardo  Menendez Ramazzini - General Manager

Date Incorporated:

N.A.

Staff:

16

Stock:

N.A.

Value:

N.A

 

Activity:

Pharmaceutical product

 

BANKS

 

Name of the Bank

Promerica

Location                                  

v. Reforma 9-55 Z. 10 Edificio Reforma 10 2do nivel, Guatemala, CA 01010

Account Number

Confidential

Comments

This information was verified by the contact person.

 

 

BUSINESS

 

HISTORY

 

The company was created in 2009.

PRINCIPAL ACTIVITY

 

The principal activity is the distribution of pharmaceutical products

Products/Services description:

 

The company divided in 3 sections:

-a wide variety of drugs.

-biomedical equipment

- and soon veterinary products

Brands:

 

Sages products, Medicall Actions, Histo.

Suppliers:

 

Sages Products

United States

 

Medicall Actions

United States

 

Histo

Argentina.

Operations area:

 

National, International

The company imports from Argentina, United States, China, India, Canada, Europe(soon)

The company does not export

Trade References:

 

The contacted person not provided phone number for the supplier beacuse he dont know.

The subject employs 16 employee(s)

LOCATION

Headquarters

 

The company is headquarterd at: 3 calle A  4-24 Zona.10 Interior Guatemala

Comments on location:

 

The administrative office and operations of the company can be found at the above listed address.

 

 

 

Shareholders - Manager - Related Companies

 

Listed at the stock exchange:

 

NO

Shareholders Parent Company(ies):

 

We could know its headquarters is located:

Edificio Multibodegas Bodega # 7 Del Cruce de Multiplaza Escazu

800 metros Noroeste, San Jose, Costa Rica

Management:

 

Mateo Estuardo Menendez Ramazzini- Legal representative and General Manager.

Samuel Sosa: Sales Manager

Mario Ramirez: Finnacial Manager

Related Companies:

 

We could know the company have related company in:

Honduras, Guatemala, Mexico, Salvador, Argentina and they have alliance in Panama and Ecuador.

 

 

Financials - COMMERCIAL TRENDS AND FORECAST

As a private company the subject does not publish any financial statements.

We have contacted with Mr.Ramazzini who provided us with the following data:

 

The company close with sales in 2011 with aproximatly USD.2.4 Millions.

Legal Filings

 The sources consulted record no detrimental legal or labor court information.

 

 

 Rating

Local credit bureau gave a normal credit rate.

 

The company is in Good Standing. This means that all local and federal taxes were paid on due date.

 

 

Final Opinion

 

This is a small sized company, which employs 16 people and has 3 years of experience in the market.

 

The principal activity of the company is the distribution and importer of all kinds of pharmaceutical products.

 

The company import from: United States, China, India, Mexico Argentina and Canada.

 

The company work with well knows banks in the country.

 

However, no financial data or credit history is available through public sources at this time.

 

There were no legal filings found against the company.

 

Considered the information gathered.

 

 

SUMMARY


FINANCIAL SUMMARY


DEBT COLLECTIONS AND PAYMENTS

 

Profitability

N.A.

Public

NO

 

Indebtedness

CONTROLLED

Payments

REGULAR

 

Cash

NORMAL

 

 

 

 

 

APPENDIX

 

Person Interviewed

 

Mr. Mateo E. Menendez Ramazzini

Position

 

General Manager

Comments

 

The contacted person provided all the information in this report.

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.54.34

UK Pound

1

Rs.87.89

Euro

1

Rs.70.13

 

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.